|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics. CA Cancer J Clin. 59:225–249. 2009.
|
|
2
|
Hsieh JT, Dinney CP and Chung LW: The
potential role of gene therapy in the treatment of bladder cancer.
Urol Clin North Am. 27:103–113. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Malmstrom PU, Sylvester RJ, Crawford DE,
et al: An individual patient data meta-analysis of the long-term
outcome of randomised studies comparing intravesical mitomycin C
versus bacillus Calmette-Guerin for non-muscle-invasive bladder
cancer. Eur Urol. 56:247–256. 2009. View Article : Google Scholar
|
|
4
|
Bohle A and Brandau S: Immune mechanisms
in bacillus Calmette-Guerin immunotherapy for superficial bladder
cancer. J Urol. 170:964–969. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ratliff TL, Ritchey JK, Yuan JJ, Andriole
GL and Catalona WJ: T-cell subsets required for intravesical BCG
immunotherapy for bladder cancer. J Urol. 150:1018–1023.
1993.PubMed/NCBI
|
|
6
|
Alexandroff AB, Jackson AM, O’Donnell MA
and James K: BCG immunotherapy of bladder cancer: 20 years on.
Lancet. 353:1689–1694. 1999.PubMed/NCBI
|
|
7
|
Witjes JA: Management of BCG failures in
superficial bladder cancer: a review. Eur Urol. 49:790–797. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rajala P, Kaasinen E, Rintala E, et al:
Cytostatic effect of different strains of Bacillus Calmette-Guerin
on human bladder cancer cells in vitro alone and in combination
with mitomycin C and interferon-alpha. Urol Res. 20:215–217. 1992.
View Article : Google Scholar
|
|
9
|
Kavoussi LR, Brown EJ, Ritchey JK and
Ratliff TL: Fibronectin-mediated Calmette-Guerin bacillus
attachment to murine bladder mucosa. Requirement for the expression
of an antitumor response. J Clin Invest. 85:62–67. 1990. View Article : Google Scholar
|
|
10
|
Horiguchi Y, Larchian WA, Kaplinsky R,
Fair WR and Heston WD: Intravesical liposome-mediated interleukin-2
gene therapy in orthotopic murine bladder cancer model. Gene Ther.
7:844–851. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jacob DA, Bahra M, Langrehr JM, et al:
Combination therapy of poly (ADP-ribose) polymerase inhibitor
3-aminobenzamide and gemcitabine shows strong antitumor activity in
pancreatic cancer cells. J Gastroenterol Hepatol. 22:738–748.
2007.
|
|
12
|
De Boer EC, Rooijakkers SJ, Schamhart DH
and Kurth KH: Cytokine gene expression in a mouse model: the first
instillations with viable bacillus Calmette-Guerin determine the
succeeding Th1 response. J Urol. 170:2004–2008. 2003.PubMed/NCBI
|
|
13
|
Tan BT, Limpens J, Koken M, Valster H and
Scheper RJ: Local administration of various cytostatic drugs after
subcutaneous immunization enhances delayed-type hypersensitivity
reaction to sheep red blood cells in mice. Scand J Immunol.
23:605–609. 1986. View Article : Google Scholar
|
|
14
|
Zitvogel L, Apetoh L, Ghiringhelli F and
Kroemer G: Immunological aspects of cancer chemotherapy. Nat Rev
Immunol. 8:59–73. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nowak AK, Robinson BW and Lake RA:
Gemcitabine exerts a selective effect on the humoral immune
response: implications for combination chemo-immunotherapy. Cancer
Res. 62:2353–2358. 2002.PubMed/NCBI
|
|
16
|
Balemans LT, Vegt PD, Steerenberg PA, et
al: Effects of sequential intravesical administration of mitomycin
C and bacillus Calmette-Guerin on the immune response in the guinea
pig bladder. Urol Res. 22:239–245. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Witjes JA, Caris CT, Mungan NA, Debruyne
FM and Witjes WP: Results of a randomized phase III trial of
sequential intravesical therapy with mitomycin C and bacillus
Calmette-Guerin versus mitomycin C alone in patients with
superficial bladder cancer. J Urol. 160:1668–1672. 1998. View Article : Google Scholar
|
|
18
|
Kaasinen E, Rintala E, Pere AK, et al:
Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or
alternating monthly interferon-alpha2B and bacillus Calmette-Guerin
for prophylaxis of recurrent papillary superficial bladder
carcinoma. J Urol. 164:47–52. 2000. View Article : Google Scholar
|
|
19
|
Kaasinen E, Wijkstrom H, Malmstrom PU, et
al: Alternating mitomycin C and BCG instillations versus BCG alone
in treatment of carcinoma in situ of the urinary bladder: a nordic
study. Eur Urol. 43:637–645. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Di Stasi SM, Giannantoni A, Giurioli A, et
al: Sequential BCG and electromotive mitomycin versus BCG alone for
high-risk superficial bladder cancer: a randomised controlled
trial. Lancet Oncol. 7:43–51. 2006.PubMed/NCBI
|
|
21
|
Ratliff TL: Role of animal models in
understanding intravesical therapy with bacille Calmette-Guerin.
Clin Infect Dis. 31(Suppl 3): 106–108. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pan CW, Shen ZJ and Ding GQ: The effect of
intravesical instillation of antifibrinolytic agents on bacillus
Calmette-Guerin treatment of superficial bladder cancer: a pilot
study. J Urol. 179:1307–1311. 2008. View Article : Google Scholar
|
|
23
|
Brandau S and Suttmann H: Thirty years of
BCG immunotherapy for non-muscle invasive bladder cancer: a success
story with room for improvement. Biomed Pharmacother. 61:299–305.
2007.PubMed/NCBI
|
|
24
|
DiPaola RS and Lattime EC: Bacillus
Calmette-Guerin mechanism of action: the role of immunity,
apoptosis, necrosis and autophagy. J Urol. 178:1840–1841. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sasaki A, Kudoh S, Mori K, Takahashi N and
Suzuki T: Are BCG effects against urinary bladder carcinoma cell
line T24 correlated with apoptosis in vitro? Urol Int. 59:142–148.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Langford LA, Cooksley CS and DeMonte F:
Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine
proliferation indices in meningiomas. Hum Pathol. 27:350–354. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Asakura T, Takano Y, Iki M, et al:
Prognostic value of Ki-67 for recurrence and progression of
superficial bladder cancer. J Urol. 158:385–388. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Santos L, Amaro T, Costa C, et al: Ki-67
index enhances the prognostic accuracy of the urothelial
superficial bladder carcinoma risk group classification. Int J
Cancer. 105:267–272. 2003. View Article : Google Scholar : PubMed/NCBI
|
